ABBOTT REALTIME HCV GENOTYPE II
FDA premarket approval P120012/S002 · decided 2013-08-13
Approval details
- PMA number
- P120012
- Supplement
- S002
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- ABBOTT REALTIME HCV GENOTYPE II
- Generic name
- Assay, genotyping, hepatitis c virus
- Applicant
- Abbott Molecular
- Date received
- 2013-07-15
- Decision date
- 2013-08-13
- Days to decision
- 29 days
- Decision code
- OK30
- Product code
- OBF
- Advisory committee
- Microbiology
- Expedited review
- No
- Location
- Des Plaines, IL
- Statement
- CHANGE TO AN IN-PROCESS TEST METHOD FOR A COMPONENT OF THE ABBOTT REALTIME HCV GENOTYPE II.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| simpli-COLLECT STI Test (K243410) | Abbott Molecular | 2025-01-30 |
| Alinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m SARS-CoV-2 CTRL Kit (09N78-086) (K241580) | Abbott Molecular | 2024-12-06 |